Takeda's Mepact backed by UK's NICE for osteosarcoma, after previous negative opinion

7 September 2011

In a U-turn by the UK drug watchdog, in its latest appraisal, the National Institute for Health and Clinical Excellence (NICE) has reversed its draft guidance and approved the use of Mepact (mifamurtide), from Japan’s largest drugmaker Takeda (TYO: 4502), for high grade non-metastatic osteosarcoma in children, adolescents and young adults aged between two and 30 (The Pharma Letter October 8, 2010).

The NICE Board has clarified how discounting is applied to its “methods guide” and, Takeda explained, this considers the cost effectiveness of a treatment when both discounting of costs and health effects is applied.

Discount clarification plus new PAS reduces QALY

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK